Compete and Win in the Age of Account Based Buying

July 15, 2019

If you’re on a B2B revenue team, it’s likely your Marketing and Sales teams are experiencing some angst these days when it comes to understanding how prospects and customers want to interact with your company. On one hand customers seem to want ultra-personalized attention on every channel, and on the other it seems as though they instantly delete every one of those painstakingly-crafted, personalized emails you send. They come to your website to download your latest eBook, but then fill out your contact form with “Mickey Mouse” from “ABC Company.”

Spotlight

Lipa Pharmaceuticals Limited

Lipa Pharmaceuticals is Australia’s leading, full service, integrated, contract manufacturer of dietary supplements and OTC pharmaceutical products. At the present time Lipa is an organization operating out of a modern, TGA, APVMA, FDA and ANVISA approved facility employing some 370 people, servicing the vast bulk of Australia’s leading brands and various overseas customers across North and South America, Europe, Asia and the Pacific region.

OTHER WHITEPAPERS
news image

How Specialty Pharmacy Can Drive Better Outcomes in Cystic Fibrosis

whitePaper | June 28, 2022

CF is a rare, autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene that encodes the CFTR protein, an anion channel normally present in the epithelial membrane.1,2

Read More
news image

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More
news image

Pharma R&D Annual Review 2022 Navigating the Landscape

whitePaper | May 7, 2022

Citeline, Welcome to Pharmaprojects' 2022 reviews of trends in pharmaceutical R&D. Take a look at the evolution of pharma R&D and in this article, examine the state of play at the start of 2022.

Read More
news image

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

Read More
news image

Pharma R&D Annual Review 2022

whitePaper | May 5, 2022

welcome to pharmaprojects'2022 review of trends in pharmaceutical R&D for 30 year now, I've been taking an anual look at the evloution of pharma

Read More

Spotlight

Lipa Pharmaceuticals Limited

Lipa Pharmaceuticals is Australia’s leading, full service, integrated, contract manufacturer of dietary supplements and OTC pharmaceutical products. At the present time Lipa is an organization operating out of a modern, TGA, APVMA, FDA and ANVISA approved facility employing some 370 people, servicing the vast bulk of Australia’s leading brands and various overseas customers across North and South America, Europe, Asia and the Pacific region.

Events